{"id":"interferon-a-2a","safety":{"commonSideEffects":[{"rate":"50-90%","effect":"Flu-like symptoms"},{"rate":"30-70%","effect":"Fatigue"},{"rate":"20-60%","effect":"Headache"},{"rate":"20-60%","effect":"Myalgia"},{"rate":"10-50%","effect":"Chills"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It does this by binding to the interferon-alpha receptor, triggering a cascade of signaling events that ultimately lead to the production of antiviral and antiproliferative proteins.","oneSentence":"Interferon-alpha-2a works by stimulating the body's immune system to fight viral infections and cancer.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:16:28.179Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple myeloma"},{"name":"Hairy cell leukemia"}]},"trialDetails":[{"nctId":"NCT01854528","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) for Treatment of Chronic Hepatitis C Infection in Treatment-experienced Adults","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-06","conditions":"Chronic Hepatitis C Infection","enrollment":148},{"nctId":"NCT02362490","phase":"PHASE4","title":"Efficacy of Peginterferon Alpha 2a Therapy in Chronic Hepatitis B Patients Being Treated With Nucleoside(Acid) Analogues","status":"UNKNOWN","sponsor":"Beijing Ditan Hospital","startDate":"2013-01","conditions":"Chronic Hepatitis B","enrollment":200},{"nctId":"NCT02387684","phase":"","title":"Efficay of Extended Peginterferon Alpha 2a Treatment in HBeAg Negative Chronic Hepatitis B Patients","status":"UNKNOWN","sponsor":"Beijing Ditan Hospital","startDate":"2012-04","conditions":"Chronic Hepatitis B","enrollment":120},{"nctId":"NCT01609010","phase":"PHASE3","title":"A Study of MabThera/Rituxan (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2002-10","conditions":"Lymphoma","enrollment":313},{"nctId":"NCT00877760","phase":"PHASE4","title":"Augmenting Response to Entecavir With Peginterferon a-2a for the Treatment of HBeAg-positive Chronic Hepatitis B","status":"COMPLETED","sponsor":"Foundation for Liver Research","startDate":"2009-08","conditions":"Chronic Hepatitis B","enrollment":184},{"nctId":"NCT01391117","phase":"PHASE1","title":"TMC649128HPC1002 - a Trial inGenotype 1 Hepatitis C Virus (HCV) - Infected Participants to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of TMC649128, Alone and Combined With Pegylated Interferon + Ribavirin","status":"TERMINATED","sponsor":"Tibotec BVBA","startDate":"2011-06","conditions":"Hepatitis C Virus","enrollment":14},{"nctId":"NCT00215839","phase":"PHASE3","title":"HRN 004- Peginterferon a-2a Plus Ribavirin for Chronic Hepatitis C Infection in HIV Infected Persons Who Have Failed to Achieve a Sustained Virologic Response Following Previous Interferon Therapy","status":"UNKNOWN","sponsor":"Hepatitis Resource Network","startDate":"","conditions":"Chronic Hepatitis C Infection in HIV Infected Persons, HIV Infections","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":10,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Roferon-A"],"phase":"phase_3","status":"active","brandName":"interferon-a-2a","genericName":"interferon-a-2a","companyName":"Hoffmann-La Roche","companyId":"hoffmann-la-roche","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Interferon-alpha-2a works by stimulating the body's immune system to fight viral infections and cancer. Used for Multiple myeloma, Hairy cell leukemia.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}